Singapur - angličtina - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - piracetam - solution - 20% w/v - piracetam 20g/100ml

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

rowex ltd - buprenorphine - transdermal patch - 20 microgram per hour - oripavine derivatives; buprenorphine

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

alissa healthcare research limited - colecalciferol - capsule, soft - 20,000 international unit(s) - vitamin d and analogues; colecalciferol

Európska únia - angličtina - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

eurovet animal health b.v. - trimethoprim; sulfamethoxazole - oral solution - 20, 100 milligram(s)/millilitre - sulfamethoxazole and trimethoprime - chickens, pigs - antibacterial

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

huvepharma nv - tylosin - granules - 20,000 international unit(s)/gram - tylosin - porcine - antibacterial

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

pharmacosmos a/ s - iron dextran - solution for injection - 20 percent weight/volume - iron, parenteral preparations - pigs - vitamins and minerals

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: povidone; lactose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Kanada - angličtina - Health Canada

glaxosmithkline inc - benzoyl peroxide - gel - 20% - benzoyl peroxide 20% - keratolytic agents